Abstract
Dupilumab-associated head and neck dermatitis (HND) is the term used to describe the new onset or exacerbation of head and neck erythema in patients receiving dupilumab for moderate-to-severe atopic dermatitis (AD). While not reported in phase three clinical trials, it was later documented in 10% of adults. An off-label trial of dupilumab in children found HDN in 5.4% of subjects. Since its approval for children six years and up, a dozen cases have been reported in children, most of them postpubertal.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
